Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBIT (2021 - 2025)

Prime Medicine filings provide 5 years of EBIT readings, the most recent being -$48.6 million for Q4 2025.

  • On a quarterly basis, EBIT fell 9.92% to -$48.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$208.4 million, a 2.91% decrease, with the full-year FY2025 number at -$208.4 million, down 2.91% from a year prior.
  • EBIT hit -$48.6 million in Q4 2025 for Prime Medicine, up from -$54.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$10.4 million in Q3 2021 to a low of -$68.0 million in Q4 2023.
  • Median EBIT over the past 5 years was -$48.5 million (2024), compared with a mean of -$44.6 million.
  • The widest YoY moves for EBIT: up 35.6% in 2022, down 203.59% in 2022.
  • Prime Medicine's EBIT stood at -$60.1 million in 2021, then skyrocketed by 35.6% to -$38.7 million in 2022, then crashed by 75.89% to -$68.0 million in 2023, then surged by 35.01% to -$44.2 million in 2024, then dropped by 9.92% to -$48.6 million in 2025.
  • The last three reported values for EBIT were -$48.6 million (Q4 2025), -$54.0 million (Q3 2025), and -$53.4 million (Q2 2025) per Business Quant data.